nodes	percent_of_prediction	percent_of_DWPC	metapath
Epoprostenol—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0722	0.126	CbGbCtD
Epoprostenol—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0679	0.119	CbGbCtD
Epoprostenol—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0679	0.119	CbGbCtD
Epoprostenol—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0614	0.107	CbGbCtD
Epoprostenol—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0614	0.107	CbGbCtD
Epoprostenol—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.053	0.0925	CbGbCtD
Epoprostenol—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0514	0.0898	CbGbCtD
Epoprostenol—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0465	0.0812	CbGbCtD
Epoprostenol—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0465	0.0812	CbGbCtD
Epoprostenol—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0446	0.0779	CbGbCtD
Epoprostenol—PTGIS—endothelium—acquired immunodeficiency syndrome	0.0121	0.141	CbGeAlD
Epoprostenol—P2RY12—blood plasma—acquired immunodeficiency syndrome	0.00968	0.113	CbGeAlD
Epoprostenol—PTGIR—endothelium—acquired immunodeficiency syndrome	0.00695	0.0811	CbGeAlD
Epoprostenol—PTGIR—blood plasma—acquired immunodeficiency syndrome	0.00618	0.072	CbGeAlD
Epoprostenol—P2RY12—blood—acquired immunodeficiency syndrome	0.00355	0.0414	CbGeAlD
Epoprostenol—PTGIS—lung—acquired immunodeficiency syndrome	0.00345	0.0403	CbGeAlD
Epoprostenol—PTGIS—nervous system—acquired immunodeficiency syndrome	0.0032	0.0373	CbGeAlD
Epoprostenol—PTGIS—central nervous system—acquired immunodeficiency syndrome	0.00308	0.0359	CbGeAlD
Epoprostenol—PTGER1—nervous system—acquired immunodeficiency syndrome	0.00297	0.0347	CbGeAlD
Epoprostenol—P2RY12—nervous system—acquired immunodeficiency syndrome	0.00288	0.0336	CbGeAlD
Epoprostenol—PTGER1—central nervous system—acquired immunodeficiency syndrome	0.00286	0.0334	CbGeAlD
Epoprostenol—P2RY12—central nervous system—acquired immunodeficiency syndrome	0.00277	0.0323	CbGeAlD
Epoprostenol—PTGIS—brain—acquired immunodeficiency syndrome	0.00244	0.0285	CbGeAlD
Epoprostenol—PTGIR—digestive system—acquired immunodeficiency syndrome	0.00237	0.0277	CbGeAlD
Epoprostenol—PTGIS—lymph node—acquired immunodeficiency syndrome	0.00236	0.0276	CbGeAlD
Epoprostenol—PTGIR—blood—acquired immunodeficiency syndrome	0.00226	0.0264	CbGeAlD
Epoprostenol—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00221	0.0257	CbGeAlD
Epoprostenol—P2RY12—brain—acquired immunodeficiency syndrome	0.0022	0.0257	CbGeAlD
Epoprostenol—PTGIR—spinal cord—acquired immunodeficiency syndrome	0.00218	0.0254	CbGeAlD
Epoprostenol—PTGIR—lung—acquired immunodeficiency syndrome	0.00198	0.0231	CbGeAlD
Epoprostenol—PTGIR—nervous system—acquired immunodeficiency syndrome	0.00184	0.0214	CbGeAlD
Epoprostenol—PTGIR—central nervous system—acquired immunodeficiency syndrome	0.00177	0.0206	CbGeAlD
Epoprostenol—PTGIR—brain—acquired immunodeficiency syndrome	0.0014	0.0164	CbGeAlD
Epoprostenol—PTGIR—lymph node—acquired immunodeficiency syndrome	0.00136	0.0158	CbGeAlD
Epoprostenol—PTGIS—Bile acid and bile salt metabolism—ALB—acquired immunodeficiency syndrome	0.00122	0.0271	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00111	0.0246	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00102	0.0226	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.00102	0.0226	CbGpPWpGaD
Epoprostenol—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000849	0.0099	CbGeAlD
Epoprostenol—P2RY12—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000842	0.0187	CbGpPWpGaD
Epoprostenol—CYP2C9—blood—acquired immunodeficiency syndrome	0.000809	0.00943	CbGeAlD
Epoprostenol—PTGIR—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000775	0.0172	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000775	0.0172	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00067	0.0149	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000653	0.0145	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000617	0.0137	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000617	0.0137	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000606	0.0135	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000558	0.0124	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000558	0.0124	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00051	0.0113	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000471	0.0105	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000469	0.0104	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000469	0.0104	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000461	0.0103	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000443	0.00983	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000443	0.00983	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000437	0.00971	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000432	0.0096	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000425	0.00943	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000425	0.00943	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000414	0.0092	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000411	0.00913	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000402	0.00893	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000402	0.00893	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000398	0.00884	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000398	0.00884	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000381	0.00846	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000381	0.00846	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000378	0.0084	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000378	0.0084	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000374	0.00832	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000352	0.00782	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000352	0.00782	CbGpPWpGaD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	0.000348	0.00774	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000344	0.00765	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000344	0.00765	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—TAT—acquired immunodeficiency syndrome	0.000342	0.0076	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000337	0.00748	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000327	0.00726	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000324	0.0072	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000324	0.0072	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000324	0.0072	CbGpPWpGaD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000324	0.0072	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000315	0.007	CbGpPWpGaD
Epoprostenol—P2RY12—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000303	0.00674	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000291	0.00646	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00029	0.00644	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00029	0.00644	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000285	0.00633	CbGpPWpGaD
Epoprostenol—P2RY12—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000282	0.00625	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CCNT1—acquired immunodeficiency syndrome	0.000278	0.00617	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000268	0.00595	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000268	0.00595	CbGpPWpGaD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000268	0.00595	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000262	0.00583	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000262	0.00583	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000262	0.00582	CbGpPWpGaD
Epoprostenol—PTGER1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000259	0.00576	CbGpPWpGaD
Epoprostenol—PTGIR—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000259	0.00576	CbGpPWpGaD
Epoprostenol—PTGIS—Adipogenesis—TNF—acquired immunodeficiency syndrome	0.000258	0.00573	CbGpPWpGaD
Epoprostenol—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.000863	CcSEcCtD
Epoprostenol—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000256	0.000863	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000256	0.000862	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000255	0.00567	CbGpPWpGaD
Epoprostenol—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000255	0.00086	CcSEcCtD
Epoprostenol—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000255	0.00086	CcSEcCtD
Epoprostenol—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000255	0.000859	CcSEcCtD
Epoprostenol—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000254	0.000858	CcSEcCtD
Epoprostenol—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000254	0.000857	CcSEcCtD
Epoprostenol—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000254	0.000856	CcSEcCtD
Epoprostenol—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000854	CcSEcCtD
Epoprostenol—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000854	CcSEcCtD
Epoprostenol—Chest pain—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000854	CcSEcCtD
Epoprostenol—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000253	0.000852	CcSEcCtD
Epoprostenol—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.000852	CcSEcCtD
Epoprostenol—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000852	CcSEcCtD
Epoprostenol—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000252	0.000849	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000252	0.000849	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000251	0.000846	CcSEcCtD
Epoprostenol—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000251	0.000845	CcSEcCtD
Epoprostenol—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000251	0.000845	CcSEcCtD
Epoprostenol—Anorexia—Delavirdine—acquired immunodeficiency syndrome	0.00025	0.000844	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00025	0.000843	CcSEcCtD
Epoprostenol—Cough—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.000843	CcSEcCtD
Epoprostenol—Pain—Indinavir—acquired immunodeficiency syndrome	0.000249	0.000838	CcSEcCtD
Epoprostenol—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000249	0.000838	CcSEcCtD
Epoprostenol—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000248	0.000837	CcSEcCtD
Epoprostenol—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000248	0.000837	CcSEcCtD
Epoprostenol—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000248	0.000836	CcSEcCtD
Epoprostenol—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000247	0.000833	CcSEcCtD
Epoprostenol—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000247	0.000833	CcSEcCtD
Epoprostenol—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000247	0.000832	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000247	0.00548	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000247	0.00548	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000247	0.00548	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000247	0.00548	CbGpPWpGaD
Epoprostenol—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000247	0.000831	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000246	0.00547	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000246	0.00547	CbGpPWpGaD
Epoprostenol—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000246	0.000829	CcSEcCtD
Epoprostenol—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000246	0.000829	CcSEcCtD
Epoprostenol—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.000828	CcSEcCtD
Epoprostenol—Syncope—Lamivudine—acquired immunodeficiency syndrome	0.000245	0.000826	CcSEcCtD
Epoprostenol—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000245	0.000826	CcSEcCtD
Epoprostenol—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000245	0.000825	CcSEcCtD
Epoprostenol—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000244	0.000823	CcSEcCtD
Epoprostenol—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000822	CcSEcCtD
Epoprostenol—Chest pain—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000822	CcSEcCtD
Epoprostenol—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000244	0.000822	CcSEcCtD
Epoprostenol—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.00082	CcSEcCtD
Epoprostenol—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000243	0.000819	CcSEcCtD
Epoprostenol—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000242	0.000817	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000242	0.000817	CcSEcCtD
Epoprostenol—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000242	0.000815	CcSEcCtD
Epoprostenol—P2RY12—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000241	0.00536	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000241	0.00535	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000241	0.00535	CbGpPWpGaD
Epoprostenol—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.00024	0.00081	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000239	0.000807	CcSEcCtD
Epoprostenol—Shock—Ritonavir—acquired immunodeficiency syndrome	0.000239	0.000806	CcSEcCtD
Epoprostenol—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000239	0.000805	CcSEcCtD
Epoprostenol—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000239	0.000804	CcSEcCtD
Epoprostenol—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000804	CcSEcCtD
Epoprostenol—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000238	0.000804	CcSEcCtD
Epoprostenol—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000803	CcSEcCtD
Epoprostenol—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000238	0.000802	CcSEcCtD
Epoprostenol—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000238	0.000802	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000238	0.000801	CcSEcCtD
Epoprostenol—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000238	0.000801	CcSEcCtD
Epoprostenol—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000237	0.000799	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.000799	CcSEcCtD
Epoprostenol—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000237	0.000798	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000237	0.00526	CbGpPWpGaD
Epoprostenol—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.000798	CcSEcCtD
Epoprostenol—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000236	0.000796	CcSEcCtD
Epoprostenol—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000236	0.000795	CcSEcCtD
Epoprostenol—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000236	0.000795	CcSEcCtD
Epoprostenol—PTGIR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000235	0.00522	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000235	0.00522	CbGpPWpGaD
Epoprostenol—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000235	0.000792	CcSEcCtD
Epoprostenol—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000235	0.000792	CcSEcCtD
Epoprostenol—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000235	0.000792	CcSEcCtD
Epoprostenol—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000235	0.000792	CcSEcCtD
Epoprostenol—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000235	0.000791	CcSEcCtD
Epoprostenol—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.00079	CcSEcCtD
Epoprostenol—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000234	0.00079	CcSEcCtD
Epoprostenol—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000234	0.000788	CcSEcCtD
Epoprostenol—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.000787	CcSEcCtD
Epoprostenol—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000233	0.000787	CcSEcCtD
Epoprostenol—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000785	CcSEcCtD
Epoprostenol—Chest pain—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000785	CcSEcCtD
Epoprostenol—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000785	CcSEcCtD
Epoprostenol—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000232	0.000783	CcSEcCtD
Epoprostenol—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000232	0.000782	CcSEcCtD
Epoprostenol—Anorexia—Ritonavir—acquired immunodeficiency syndrome	0.000232	0.000781	CcSEcCtD
Epoprostenol—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000231	0.00078	CcSEcCtD
Epoprostenol—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000779	CcSEcCtD
Epoprostenol—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000231	0.000778	CcSEcCtD
Epoprostenol—Shock—Saquinavir—acquired immunodeficiency syndrome	0.00023	0.000776	CcSEcCtD
Epoprostenol—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.00023	0.000775	CcSEcCtD
Epoprostenol—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00023	0.000775	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000229	0.0051	CbGpPWpGaD
Epoprostenol—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000773	CcSEcCtD
Epoprostenol—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000229	0.000773	CcSEcCtD
Epoprostenol—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000229	0.000772	CcSEcCtD
Epoprostenol—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000229	0.000771	CcSEcCtD
Epoprostenol—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000228	0.00077	CcSEcCtD
Epoprostenol—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000228	0.000767	CcSEcCtD
Epoprostenol—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000227	0.000767	CcSEcCtD
Epoprostenol—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000227	0.000766	CcSEcCtD
Epoprostenol—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000227	0.000766	CcSEcCtD
Epoprostenol—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000765	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	0.000227	0.00504	CbGpPWpGaD
Epoprostenol—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.000765	CcSEcCtD
Epoprostenol—Rash—Stavudine—acquired immunodeficiency syndrome	0.000227	0.000764	CcSEcCtD
Epoprostenol—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000227	0.000764	CcSEcCtD
Epoprostenol—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000226	0.000764	CcSEcCtD
Epoprostenol—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.000762	CcSEcCtD
Epoprostenol—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000226	0.000762	CcSEcCtD
Epoprostenol—Headache—Stavudine—acquired immunodeficiency syndrome	0.000225	0.000759	CcSEcCtD
Epoprostenol—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000225	0.000759	CcSEcCtD
Epoprostenol—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000225	0.000758	CcSEcCtD
Epoprostenol—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000225	0.000757	CcSEcCtD
Epoprostenol—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000225	0.000757	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000225	0.000757	CcSEcCtD
Epoprostenol—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000224	0.000756	CcSEcCtD
Epoprostenol—Rash—Abacavir—acquired immunodeficiency syndrome	0.000223	0.000753	CcSEcCtD
Epoprostenol—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000223	0.000752	CcSEcCtD
Epoprostenol—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000752	CcSEcCtD
Epoprostenol—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000223	0.000752	CcSEcCtD
Epoprostenol—Anorexia—Saquinavir—acquired immunodeficiency syndrome	0.000223	0.000752	CcSEcCtD
Epoprostenol—PTGER1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000222	0.00493	CbGpPWpGaD
Epoprostenol—PTGIR—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000222	0.00493	CbGpPWpGaD
Epoprostenol—Headache—Abacavir—acquired immunodeficiency syndrome	0.000222	0.000748	CcSEcCtD
Epoprostenol—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000222	0.000747	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000221	0.000746	CcSEcCtD
Epoprostenol—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000221	0.000746	CcSEcCtD
Epoprostenol—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000221	0.000745	CcSEcCtD
Epoprostenol—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.00022	0.000741	CcSEcCtD
Epoprostenol—Shock—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.00074	CcSEcCtD
Epoprostenol—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000219	0.000738	CcSEcCtD
Epoprostenol—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.000737	CcSEcCtD
Epoprostenol—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000218	0.000736	CcSEcCtD
Epoprostenol—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000736	CcSEcCtD
Epoprostenol—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000218	0.000735	CcSEcCtD
Epoprostenol—PTGIR—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000218	0.00484	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000218	0.00484	CbGpPWpGaD
Epoprostenol—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.000732	CcSEcCtD
Epoprostenol—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000217	0.000732	CcSEcCtD
Epoprostenol—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000217	0.000731	CcSEcCtD
Epoprostenol—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.00073	CcSEcCtD
Epoprostenol—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.000728	CcSEcCtD
Epoprostenol—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000216	0.000727	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000215	0.000724	CcSEcCtD
Epoprostenol—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000214	0.000722	CcSEcCtD
Epoprostenol—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000214	0.000722	CcSEcCtD
Epoprostenol—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000214	0.000721	CcSEcCtD
Epoprostenol—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000214	0.000721	CcSEcCtD
Epoprostenol—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000214	0.00072	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000213	0.000718	CcSEcCtD
Epoprostenol—Anorexia—Lamivudine—acquired immunodeficiency syndrome	0.000213	0.000717	CcSEcCtD
Epoprostenol—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000212	0.000713	CcSEcCtD
Epoprostenol—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000211	0.000712	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—IFNA1—acquired immunodeficiency syndrome	0.000211	0.00469	CbGpPWpGaD
Epoprostenol—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00021	0.000709	CcSEcCtD
Epoprostenol—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000708	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.00021	0.000707	CcSEcCtD
Epoprostenol—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000706	CcSEcCtD
Epoprostenol—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000209	0.000704	CcSEcCtD
Epoprostenol—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000209	0.000703	CcSEcCtD
Epoprostenol—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000703	CcSEcCtD
Epoprostenol—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.000703	CcSEcCtD
Epoprostenol—PTGIS—Adipogenesis—IL6—acquired immunodeficiency syndrome	0.000208	0.00462	CbGpPWpGaD
Epoprostenol—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000701	CcSEcCtD
Epoprostenol—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000208	0.0007	CcSEcCtD
Epoprostenol—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000208	0.0007	CcSEcCtD
Epoprostenol—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000208	0.0007	CcSEcCtD
Epoprostenol—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000208	0.0007	CcSEcCtD
Epoprostenol—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000207	0.000697	CcSEcCtD
Epoprostenol—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000206	0.000694	CcSEcCtD
Epoprostenol—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000206	0.000693	CcSEcCtD
Epoprostenol—P2RY12—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000204	0.00453	CbGpPWpGaD
Epoprostenol—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000203	0.000685	CcSEcCtD
Epoprostenol—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000203	0.000685	CcSEcCtD
Epoprostenol—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000202	0.000682	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.000681	CcSEcCtD
Epoprostenol—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000202	0.00068	CcSEcCtD
Epoprostenol—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000202	0.00068	CcSEcCtD
Epoprostenol—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000675	CcSEcCtD
Epoprostenol—Pain—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000674	CcSEcCtD
Epoprostenol—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.0002	0.000674	CcSEcCtD
Epoprostenol—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.000671	CcSEcCtD
Epoprostenol—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000199	0.00067	CcSEcCtD
Epoprostenol—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000199	0.00067	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.00067	CcSEcCtD
Epoprostenol—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.000669	CcSEcCtD
Epoprostenol—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.000664	CcSEcCtD
Epoprostenol—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000197	0.000664	CcSEcCtD
Epoprostenol—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000197	0.000664	CcSEcCtD
Epoprostenol—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000196	0.000662	CcSEcCtD
Epoprostenol—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000196	0.00066	CcSEcCtD
Epoprostenol—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000194	0.000655	CcSEcCtD
Epoprostenol—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000194	0.000654	CcSEcCtD
Epoprostenol—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000194	0.000653	CcSEcCtD
Epoprostenol—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000193	0.000651	CcSEcCtD
Epoprostenol—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000193	0.000649	CcSEcCtD
Epoprostenol—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000648	CcSEcCtD
Epoprostenol—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000192	0.000648	CcSEcCtD
Epoprostenol—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.000648	CcSEcCtD
Epoprostenol—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000192	0.000648	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000645	CcSEcCtD
Epoprostenol—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.000643	CcSEcCtD
Epoprostenol—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000191	0.000643	CcSEcCtD
Epoprostenol—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000189	0.000636	CcSEcCtD
Epoprostenol—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000188	0.000633	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000188	0.00417	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000188	0.00417	CbGpPWpGaD
Epoprostenol—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000186	0.000627	CcSEcCtD
Epoprostenol—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000186	0.000626	CcSEcCtD
Epoprostenol—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000186	0.000626	CcSEcCtD
Epoprostenol—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.000623	CcSEcCtD
Epoprostenol—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000185	0.000623	CcSEcCtD
Epoprostenol—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000185	0.000623	CcSEcCtD
Epoprostenol—P2RY12—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	0.000184	0.00409	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000184	0.00408	CbGpPWpGaD
Epoprostenol—Rash—Indinavir—acquired immunodeficiency syndrome	0.000183	0.000618	CcSEcCtD
Epoprostenol—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000183	0.000617	CcSEcCtD
Epoprostenol—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.000615	CcSEcCtD
Epoprostenol—Headache—Indinavir—acquired immunodeficiency syndrome	0.000182	0.000614	CcSEcCtD
Epoprostenol—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000182	0.000612	CcSEcCtD
Epoprostenol—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.00018	0.000606	CcSEcCtD
Epoprostenol—P2RY12—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.00018	0.00399	CbGpPWpGaD
Epoprostenol—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000179	0.000604	CcSEcCtD
Epoprostenol—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000177	0.000598	CcSEcCtD
Epoprostenol—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000595	CcSEcCtD
Epoprostenol—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000176	0.000595	CcSEcCtD
Epoprostenol—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000175	0.000589	CcSEcCtD
Epoprostenol—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000174	0.000588	CcSEcCtD
Epoprostenol—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000174	0.000586	CcSEcCtD
Epoprostenol—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000584	CcSEcCtD
Epoprostenol—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000173	0.000583	CcSEcCtD
Epoprostenol—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000173	0.000582	CcSEcCtD
Epoprostenol—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000172	0.000581	CcSEcCtD
Epoprostenol—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000172	0.00058	CcSEcCtD
Epoprostenol—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000172	0.00058	CcSEcCtD
Epoprostenol—PTGER1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000169	0.00376	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000169	0.00376	CbGpPWpGaD
Epoprostenol—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000168	0.000566	CcSEcCtD
Epoprostenol—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000167	0.000563	CcSEcCtD
Epoprostenol—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000166	0.00056	CcSEcCtD
Epoprostenol—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000559	CcSEcCtD
Epoprostenol—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000166	0.000558	CcSEcCtD
Epoprostenol—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000165	0.000558	CcSEcCtD
Epoprostenol—PTGIR—Hemostasis—CSF2—acquired immunodeficiency syndrome	0.000165	0.00367	CbGpPWpGaD
Epoprostenol—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000165	0.000555	CcSEcCtD
Epoprostenol—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000164	0.000554	CcSEcCtD
Epoprostenol—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000163	0.00055	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000162	0.00359	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000161	0.00358	CbGpPWpGaD
Epoprostenol—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000161	0.000542	CcSEcCtD
Epoprostenol—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.00016	0.00054	CcSEcCtD
Epoprostenol—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00016	0.000539	CcSEcCtD
Epoprostenol—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000158	0.000532	CcSEcCtD
Epoprostenol—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000156	0.000526	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000155	0.00344	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000155	0.00344	CbGpPWpGaD
Epoprostenol—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000155	0.000521	CcSEcCtD
Epoprostenol—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000154	0.000521	CcSEcCtD
Epoprostenol—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000516	CcSEcCtD
Epoprostenol—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000153	0.000516	CcSEcCtD
Epoprostenol—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000153	0.000515	CcSEcCtD
Epoprostenol—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000152	0.000513	CcSEcCtD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000151	0.00336	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000151	0.00336	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000149	0.00331	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000149	0.00331	CbGpPWpGaD
Epoprostenol—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000149	0.000501	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000148	0.00329	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000148	0.00329	CbGpPWpGaD
Epoprostenol—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000148	0.000497	CcSEcCtD
Epoprostenol—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000497	CcSEcCtD
Epoprostenol—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000497	CcSEcCtD
Epoprostenol—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000147	0.000494	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000146	0.00325	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CXCR4—acquired immunodeficiency syndrome	0.000146	0.00324	CbGpPWpGaD
Epoprostenol—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000144	0.000487	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000142	0.00316	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000142	0.00316	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000142	0.00316	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000142	0.00316	CbGpPWpGaD
Epoprostenol—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000142	0.000478	CcSEcCtD
Epoprostenol—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000474	CcSEcCtD
Epoprostenol—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000141	0.000474	CcSEcCtD
Epoprostenol—P2RY12—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00014	0.00311	CbGpPWpGaD
Epoprostenol—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00014	0.000471	CcSEcCtD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000139	0.0031	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000139	0.0031	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000139	0.0031	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000139	0.0031	CbGpPWpGaD
Epoprostenol—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000139	0.000468	CcSEcCtD
Epoprostenol—P2RY12—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000138	0.00306	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000138	0.00306	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000135	0.00299	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000135	0.00299	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	0.000134	0.00298	CbGpPWpGaD
Epoprostenol—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000133	0.000447	CcSEcCtD
Epoprostenol—PTGER1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000129	0.00286	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000129	0.00286	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000127	0.00281	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000127	0.00281	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000127	0.00281	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000127	0.00281	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000117	0.0026	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000115	0.00256	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000113	0.00252	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—ALB—acquired immunodeficiency syndrome	0.000108	0.00239	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000106	0.00236	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000106	0.00236	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	0.000106	0.00235	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000105	0.00232	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000104	0.00232	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000104	0.00232	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000104	0.00231	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000103	0.00229	CbGpPWpGaD
Epoprostenol—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000102	0.00226	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CCR5—acquired immunodeficiency syndrome	0.0001	0.00222	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.63e-05	0.00214	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.63e-05	0.00214	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.55e-05	0.00212	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.55e-05	0.00212	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.55e-05	0.00212	CbGpPWpGaD
Epoprostenol—P2RY12—Hemostasis—IL2—acquired immunodeficiency syndrome	9.49e-05	0.00211	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.48e-05	0.00211	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.48e-05	0.00211	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	9.43e-05	0.00209	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.79e-05	0.00195	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.79e-05	0.00195	CbGpPWpGaD
Epoprostenol—PTGIR—Hemostasis—IL2—acquired immunodeficiency syndrome	8.73e-05	0.00194	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.67e-05	0.00193	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.67e-05	0.00193	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.64e-05	0.00192	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.12e-05	0.00181	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.12e-05	0.00181	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.95e-05	0.00177	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.95e-05	0.00177	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.48e-05	0.00166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.48e-05	0.00166	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.48e-05	0.00166	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.48e-05	0.00166	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—CD4—acquired immunodeficiency syndrome	6.28e-05	0.00139	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.18e-05	0.00137	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.09e-05	0.00135	CbGpPWpGaD
Epoprostenol—P2RY12—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6e-05	0.00133	CbGpPWpGaD
Epoprostenol—PTGIS—Metabolism—ALB—acquired immunodeficiency syndrome	5.97e-05	0.00133	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.69e-05	0.00126	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.69e-05	0.00126	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.6e-05	0.00124	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.6e-05	0.00124	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.57e-05	0.00124	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	5.53e-05	0.00123	CbGpPWpGaD
Epoprostenol—PTGIR—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.52e-05	0.00123	CbGpPWpGaD
Epoprostenol—PTGER1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.52e-05	0.00123	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.45e-05	0.00121	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.12e-05	0.00114	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.12e-05	0.00114	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.01e-05	0.00111	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.01e-05	0.00111	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	4.7e-05	0.00104	CbGpPWpGaD
Epoprostenol—PTGIS—Disease—IL6—acquired immunodeficiency syndrome	3.4e-05	0.000754	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.22e-05	0.000715	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.2e-05	0.000711	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.96e-05	0.000658	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.96e-05	0.000658	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.95e-05	0.000655	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.95e-05	0.000655	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	2.16e-05	0.000481	CbGpPWpGaD
Epoprostenol—P2RY12—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.89e-05	0.00042	CbGpPWpGaD
Epoprostenol—PTGIR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.74e-05	0.000387	CbGpPWpGaD
Epoprostenol—PTGER1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.74e-05	0.000387	CbGpPWpGaD
Epoprostenol—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	9.64e-06	0.000214	CbGpPWpGaD
